Cassava Laying off One-third of Staff to Curb Expenses
Cassava Sciences Provides Update on Phase 3 REFOCUS-ALZ Study and Workforce Reduction Plans
Express News | Cassava- Topline Data From Phase 3 Refocus-Alz Study of Simufilam in Patients With Mild-to-Moderate Alzheimer's Disease Expected Late Q1/Early Q2 2025
Express News | Cassava Sciences Inc: In Final Stages of Discontinuing Refocus-Alz Study
Express News | Cassava Sciences Inc: Implementing Cost Curtailment Including a Workforce Reduction of Approximately 33%
Express News | Cassava Sciences Provides a Business Update
Zahid007 : whats target for sava ? and how much you made with this amazing portfolio